Copyright 2004 John Wiley & Sons, Ltd. Keywords exenatide; exendin-4; type 2 diabetes; incretin mimetic; dose- escalation; mitigation of side effects; reduction of adverse events Introduction Exenatide (exendin-4) is an incretin mi metic having glucoregulatory activi- ties similar to those of native glucagon-like peptide-1 (GLP-1). These actions Copyright 2004 John Wiley & Sons, Ltd.